Minimally invasive management of adult craniopharyngiomas: An analysis of our series and review of literature

Gazanfar Rahmathulla1,2, Gene H. Barnett1

Departments of Neurosurgery, 1The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological and Tausigg Cancer Institutes, Cleveland Clinic, Cleveland, Ohio, United States, 2Mayo Clinic, Jacksonville, Florida

E-mail: Gazanfar Rahmathulla - rahmathulla.gazanfar@mayo.edu; *Gene H. Barnett - barnetg@ccf.org

*Corresponding author

Received: 14 March 13  Accepted: 08 May 13  Published: 20 November 13

Abstract

Background: Craniopharyngiomas (CPs) are slow growing tumors with an incidence of between 1.2% and 4.6%, having a bimodal age distribution typically peaking in childhood and in adults between 45 and 60 years. Recurrences occur even after documented gross total resections necessitating a combination of therapeutic strategies. Obtaining a cure of this tumor in adults without producing major side effects continues to remain elusive.

Methods: We describe our results in 11 patients with CP treated in a minimally invasive fashion using a combination of techniques like burr hole aspiration, Ommaya reservoir placement, ventriculo-peritoneal (VP) shunting and focal radiation (Gamma Knife stereotactic radiosurgery/Intensity modulated radiotherapy [GKRS/IMRT]).

Results: Visual function remained intact in all patients; endocrine status remained stable with two patients developing new postoperative diabetes insipidus. There was no periprocedural morbidity or mortality, with hospital stays for any in-patient procedure being 48 hours or less.

Conclusions: Minimally invasive techniques such as cyst aspiration, insertion of a catheter with Ommaya reservoir, when combined with stereotactic radiosurgery/IMRT is an effective and safe option for management and long-term control of adult CPs. We believe the Ommaya catheter by itself could act as a stent, creating a tract allowing gradual drainage of cyst fluid and stabilization without necessitating any further interventions in selected cases.

Key Words: Craniopharyngioma, focal radiotherapy, minimally invasive, radiosurgery

INTRODUCTION

Craniopharyngiomas (CPs) are benign, slow growing tumors whose ideal management remains controversial and challenging. They arise from remnants of the craniopharyngeal duct and/or Rathkes cleft. These tumors have an incidence of between 1.2% and 4.6%[8,48] with a bimodal age distribution, one peak occurring in children and the other in adults between the 4th and 6th decades. These tumors are located close to the visual apparatus, hypothalamus, pituitary stalk, 3rd ventricle, and vasculature from the circle of Willis. The proximity...
of the tumor and its adherence to these critical structures makes complete microsurgical removal without neurological deterioration difficult.\textsuperscript{[17,87]} Although these tumors are histologically benign, recurrence rates up to 57\% have been reported even after surgical gross total resections, due to their invasiveness.

Traditional management of these tumors is microsurgical total resection. However, their propensity to recur had necessitated a combination of strategies such as local chemotherapy (e.g., bleomycin)\textsuperscript{[86]} and frequent cyst aspirations. The good outcomes seen in the 1990s with minor surgical interventions followed by radiotherapy brought an alternative paradigm to the management of these tumors.\textsuperscript{[11,61,64]} With technological improvements and better platforms for conformal radiation delivery, stereotactic radiosurgery (SRS) has been used to manage recurrent or residual tumors and has been reported to be an effective and safe addition in the treatment of these tumors.\textsuperscript{[11,61,64]} With a median 10-year survival rates for these patients being as high as 85-93\%,\textsuperscript{[83]} safe therapeutic interventions are essential in order to maintain the quality of life of these patients. Individualized treatment strategies have to be used depending on the size, location, calcification, relation to adjacent vascular and neural structures, and the presence of a cystic component. The low incidence of these tumors coupled with the above mentioned tumor factors, along with numerous available interventions make it difficult to statistically quantify the efficacy of either an initial radical resection or graded sequential multi-modality treatments, making it difficult to produce guidelines for managing these tumors.

The aim of this study was to present our outcomes treating adult CP patients using a combination of minimally invasive strategies including cyst aspiration (with or without Ommaya reservoir system insertion), ventriculo-peritoneal (VP) shunting and either upfront or adjuvant conformal radiotherapy and a review of current literature.

MATERIALS AND METHODS

An institutional review board (IRB) approved retrospective chart review of all patients undergoing treatment for CPs between 1995 and 2010. Fifty-two patients with a diagnosis of CP underwent management at our institute between 1995 and 2010. We included all adult patients (>21 years) with an imaging diagnosis of CP with a predominantly cystic component, had undergone either a biopsy with cyst drainage, insertion of a catheter or Ommaya reservoir system, VP shunt or radiation therapy (RT) as their procedures, without any prior surgical intervention categorizing all these procedures together as minimally invasive. Out of the 52 patients, 11 patients were treated using the minimally invasive strategy. The median age for all CP patients at diagnosis was 49 years (range 24-80) with an equal number of male and female patients. In the minimally invasive treated group there were five male and six female patients with a median age of 58 years (range 24-80 years). Seven patients had histologically proven CPs with stereotactic biopsy (4 adamantinomatous, 2 WHO grade I, and 1 papillary) and of the remaining four patients, two underwent a stereotactic biopsy aspiration with characteristic machine oil fluid but no tissue sample and two patients in the cohort had undergone VP shunting elsewhere. For these 4/11 patients’ clinical findings, laboratory workup, and neuroimaging was the basis for further management. In most cases after biopsy-cyst aspiration, patients were followed with magnetic resonance imaging (MRI) studies initially at 1 month, then every 3 months for a year and then every 6 months for a year, and subsequently at yearly intervals to evaluate tumor size and to determine the feasibility of early intervention with focal RT (Gamma knife radiosurgery or Intensity modulated radiotherapy [IMRT]). Detailed neuroendocrinological assessment was done prior to and following treatment. A brief description of three representative cases is presented.

CASE REPORTS

Case 1

HS, a 46-year-old male presented with decreased vision in his left eye along with impotence and diminished energy levels of about 3 months duration. His endocrine evaluation revealed pan-hypopituitarism. He was diagnosed with a suprasellar mass, mixed solid-cystic [Figure 1a and b] and underwent an image-guided stereotactic (using skull fiducials) brain biopsy and aspiration of the cyst, which contained about 4 cc of oily fluid. Histologic review revealed a papillary CP. One month later he underwent Gamma Knife radiosurgery on the residual tumor [Figure 2]. Postoperatively he did well with a gradual improvement in his vision and a decrease in tumor size as seen on imaging 5 years following initial treatment [Figure 3a and b]. His pan-hypopituitarism remained stable and he is currently being managed with hormone replacement therapy.

Six years following Gamma Knife stereotactic radiosurgery (GKRS) treatment, his tumor recurred and he underwent an extended transphenoidal surgery presently remaining free of radiographic tumor.

Case 2

MO, a 24-year-old male presented at an outside hospital with headaches of a few months in duration with a loss of libido and decreased energy levels. His endocrine workup revealed hypopituitarism and imaging showed a 2.5 cm sellar-suprasellar solid cystic mass for which he underwent...
follow-up at 9 years continues with the patient remaining stable and requiring no further interventions.

**Case 3**

MC, a 69-year-old female who following a head injury, was diagnosed with an incidental suprasellar cystic-solid mass. She remained asymptomatic for 4 years, subsequently developing diminished vision along with weight gain with an increase in lesion size. She underwent biopsy-aspiration of the cyst followed by Gamma Knife radiosurgery a month later. Subsequently 4 months later she developed a cyst recurrence on imaging and underwent Ommaya reservoir insertion, having no associated clinical changes. On follow-up, her MRI revealed an increase in the size of the cyst. Although further aspiration of the cystic component via the Ommaya reservoir was advised, she declined any intervention. Repeat imaging revealed a spontaneous decrease in the size of the cystic component that remained stable over time and required no further intervention.

**RESULTS**

All the patients were evaluated clinically for their neurological, endocrine status, and MRI imaging at our institution. Initial follow-up imaging was obtained at 1 month, then every 3 months for a year, subsequently at 6 months intervals for a year, and then at yearly intervals. Earlier imaging was done in cases of symptomatic worsening or if progression was observed on their MRIs. In patients with stable disease yearly clinical and neuroimaging follow-up was performed.

**Clinical response**

There were no procedural or perioperative associated morbidity or mortality. The mean follow-up period in these patients was 66 months (range 2-144 months) and the median was 60 months. There was always a residual component on posttreatment MRI scans because the interventions did not include gross surgical resection. Two patients who were 77 and 78 years at the time of initial diagnosis and treatment were lost to follow-up after a period of 11 and 9 years, respectively. On the last clinic visit, they had no progression of their disease and were 88 and 87 years old. The remaining patients continue to be observed with regular clinic visits and with no mortalities in this group.

Of the 11 patients, 8 underwent stereotactic biopsy aspiration followed by clinical and neuroimaging follow-up, 4 patients had insertion of an Ommaya reservoir and aspiration of the cystic component either as an initial or subsequent procedure. Duration of in-hospital stay for these procedures ranged from 24 to 48 hours. Four (4/11) patients had GKRS, and three (3/11) had IMRT following tumor cyst decompression. The choice of RT was determined by the dose constraints and proximity...
of the tumor to the optic nerves. One patient (1/11) in the cohort was treated at an outside facility with upfront GKRS (case no. 7). This patient subsequently developed visual deterioration associated with tumor progression and was treated with an IMRT boost [Table 1]. At our Institute (N = 4), the patients who had GKRS for tumor control had tumor volumes ranging from 1.6 to 4.1 cc (mean 2.33 cc). Maximum dose to the optic apparatus was less than 9 Gy, with a mean maximum tumor dose of 19.2 Gy, and a mean marginal dose of 10.75 Gy using 6-22 isocenters [Table 2]. The three patients who underwent initial IMRT received a standard dose of 54 Gy in in daily fractions of 1.8-2.0 Gy. One patient (9) treated early in the series received 32P intracavitary irradiation for tumor control.

Serial neuroendocrine evaluations revealed anterior pituitary hormone dysfunction in 8/11 of the patients. Two patients had improvement of their preexisting partial DI after intervention. Two patients (7 and 10) underwent VP shunts for obstructive hydrocephalus as the only invasive procedure prior to initiating RT. There was no formal neuropsychological evaluation prior to or after radiation treatments, making it difficult to objectively assess cognitive decline or improvement.

Response of the tumor to minimally invasive interventions
The tumors treated, were mixed tumors having both a solid as well as a predominantly cystic component. In our series, we defined progression as a symptomatic worsening with corresponding changes in neuroimaging after the last intervention, stable disease in cases where there was no symptomatic worsening but there could be fluctuation in the size of the cyst on MRI, and a complete response when there was neither symptomatic nor neuroimaging changes in the tumor. According to our criteria, there was one patient (1/11) in whom symptomatic progression occurred, along with radiological worsening of the solid component about 6 years following his treatment, at which time the tumor was amenable to surgical intervention (case 1). There were five (5/11) patients with stable disease, in whom two (2/11) had a fluctuation in cyst size on follow-up imaging. These

| Patient | Age/sex | Biopsy-aspiration | Ommaya insertion | GKRS | No of invasive interventions | IMRT | Chemo | Follow-up (months) |
|---------|---------|--------------------|------------------|------|-----------------------------|------|-------|-------------------|
| 1       | 46/M    | +                  | -                | +    | 2                           | -    | -     | 72                |
| 2       | 24/M    | +                  | -                | +    | 1                           | -    | -     | 120               |
| 3       | 69/F    | +                  | +                | +    | 2                           | -    | -     | 48                |
| 4       | 58/M    | +                  | -                | +    | 1                           | -    | -     | 60                |
| 5       | 31/M    | +                  | +                | -    | 4                           | +    | -     | 53                |
| 6       | 49/F    | +                  | -                | -    | 1                           | -    | -     | 2                 |
| 7       | 62/F    | -                  | -                | +    | 1 (VP shunt)                | +    | -     | 84                |
| 8       | 55/M    | +                  | +                | -    | 2                           | -    | -     | 12                |
| 9       | 78/F    | +                  | +                | -    | 2                           | 32P  | -     | 108               |
| 10      | 77/F    | -                  | -                | -    | 1 (VP shunt)                | +    | -     | 144               |
| 11      | 66/F    | +                  | -                | -    | 1                           | +    | -     | 24                |

VP: Ventriculo-peritoneal, IMRT: Intensity modulated radiation therapy, GKRS: Gamma knife radiosurgery

| Patient | Max dose Gy | Margin dose Gy | IDL (%) | Vol (cc) | Visual status pretreatment | Visual status on follow-up | IMRT dose | Endocrine status on follow-up |
|---------|--------------|----------------|---------|----------|-----------------------------|---------------------------|----------|------------------------------|
| 1       | 16           | 9              | 55      | 4.1      | VA/VF ↓                     | ↔/↓                      | -        | Panhypopituitarism            |
| 2       | 29.4         | 15             | 51      | 1.6      | ↔                           | ↔                        | -        | Hypothyroid                  |
| 3       | 15.9         | 9              | 57      | 1.8      | ↓                           | ↔/↑                      | -        | Hypothyroid and hypogonadism |
| 4       | 15.4         | 10             | 65      | 1.8      | ↓                           | ↑                        | -        | Panhypopituitarism            |
| 5       | -            | -              | -       | -        | ↓                           | ↑                        | 54 Gy    | Panhypopituitarism            |
| 6       | -            | -              | -       | -        | ↓                           | ↑                        | -        | Stable                       |
| 7       | -            | 15             | 50      | 2.5      | ↔                           | ↔                        | 51 Gy    | Stable                       |
| 8       | -            | -              | -       | -        | ↓                           | ↑                        | -        | Hypogonadism                 |
| 9       | -            | -              | -       | -        | ↓                           | ↔                        | 32 P     | Stable                       |
| 10      | -            | -              | -       | -        | ↔                           | ↔                        | 54 Gy    | Stable                       |
| 11      | -            | -              | -       | -        | ↓                           | ↑                        | 54 Gy    | Stable                       |

Table 1: Summary of clinical interventions and duration of follow-up

Table 2: Radiosurgery/IMRT treatment data with pre- and posttreatment dimensions and endocrine status
two patients continue to remain clinically stable from their baseline initial evaluations, and at present have reduced cystic components without the need for further intervention. One (1/11) patient has progressed on imaging without symptomatic clinical worsening and continues to be observed. Two (2/11) patients have stable tumors on imaging following biopsy-cyst aspiration without radiation (case no. 6 and 8) and continue to be observed. Five (5/11) patients have been defined as having a complete response according to our criteria (case nos. 4, 7, 9, 10, 11), as they have no clinical or MRI changes after receiving focal RT (GKRS/IMRT or \(^{32}\)P). A fluctuation in the cyst dimensions is a common occurrence, subsequent to radiotherapy and although patients may not be symptomatic, they requiring diligent follow-up. Hence according to our criteria, only one patient (case no. 1) had a true progression, whereas the others are either stable or improved.

**Endocrine outcomes**

Eight patients (73%) had one or more endocrine deficits on presentation, hypogonadism being the most common at presentation five (5/11, 45%). There were two (2/11, 18%) who presented with hypothyroidism and (3/11, 27.2%) had pan-hypopituitarism. Diabetes insipidus was seen at presentation in one (1/11, 9%) patient (case 5).

In the course of their treatments, two new patients had developed pan-hypopituitarism and required hormone supplementation (preoperatively 3/11 (27.2%); postoperatively 5/11 (45%)) following intervention. The patients with hypothyroidism required hormone replacement during their follow-up. Transient diabetes insipidus was seen in one patient following a biopsy (case no. 8) and was permanent in one (case no. 5). The endocrine evaluation and management was performed by the neuroendocrinologist in the pre- and postoperative periods.

**Visual outcomes**

Eight patients (73%) had a visual field defect at presentation. Visual deficits included blurring of vision, diplopia, and field cuts and all affected patients were symptomatic. Six (6/8) of these patients had improvement in vision at last follow-up irrespective of the type of intervention, one had no change and one patient had a worsening of vision. Although one patient (case 7) did undergo GKRS and subsequently IMRT, her vision remained stable on follow-up.

**Discharge time and associated medical morbidity**

In-hospital stay was required for performing a biopsy, insertion of an Ommaya reservoir or placement of a VP shunt. Patients who underwent any of these procedures were discharged within 48 hours, with no associated complications related to hospital stay. Endocrine issues were taken care of by the neuroendocrinologist on an out-patient follow up basis. For adjuvant radiation procedures no hospital admission was required.

**DISCUSSION**

CPs are histologically benign tumors involving the sellar-suprasellar region, but often invading or adherent to adjacent critical structures. The intimate association between the tumor and the optic apparatus, hypothalamus, and pituitary gland makes treating them challenging. In reports published prior to the 1980s, recurrence rates for PCs varied from 30% to 50%.[9,10,28,87] Although numerous technological advances in image-guided surgical systems and micro-techniques have been made since then, the results are only slightly better.[6,17,18,39,41,42,90,81] With a variety of therapeutic options available to treat these patients, do select subgroup adult patients with PCs need aggressive microsurgery with a gross resection as a goal?

Of the various therapeutic strategies available, microsurgical resection is still considered to be the mainstay of management for adult patients with PCs.[27] Gross total resections may give rise to a cure, but major series reported have a success rate ranging between 30% and 97%.[28,35,38,68,75,78,79] Recurrence rates vary between 5% and 10% in some series to as high as 50% following so called “gross total” resections. The success rates of gross total resections reported in a large recently reported single center series is 95.6% for tumors with a diameter of less than 6 cm and 58.8% for those with diameters greater than 6 cm.[72] Other early primarily operative series such as that of Konnovolov et al.[35] report complete resection rates of 64% with other series of Sweet et al.[75] and Samii et al.[88] reporting 93% and 97%, respectively. The recurrence rates for these tumors range from 0% to 26% following gross total resections,[15,46] with the highest risk of recurrence being in the first 3 years following surgery.[11,88] Prasad et al.[64] in their 30-year review reported only 11 (35.5%) of the 31 series achieved more than a 50% radical resection rate. The operative mortality in published large series ranges from 0% to 5.4%,[18,29,83] especially after resecting tumors invading the hypothalamus,[67] with Yasargil[87] in his series reporting 16.7% mortality due to more aggressive total removal in all their cases. The morbidity rates range from 12% to 60% and include hormonal deficiency, cerebrospinal fluid (CSF) leaks, visual dysfunction, hypothalamic–metabolic dysfunction, and cognitive dysfunction.[21,47,88] Recurrent tumors are more difficult to operate upon and are associated with significantly lower progression-free survival rates as well as higher mortality and morbidity rates. Patients who undergo transphenoidal surgery have lower mortality rates when compared with the transcranial route.[18] The results of the outcomes with various major microsurgical series reported in literature are described in Table 3.

Although our cohort of patients is small, we observed good long-term control rates as seen by the duration
of follow-up [Table 1]. The absence of procedural and periprocedural morbidity, good long-term tumor control, minimal acute and late endocrine, visual toxicity, and early hospital discharge make these minimalistic procedures a viable option in the multi-modality treatment of CPs in adult patients. These patients can resume their baseline activities, being mobilized early following these interventions, thus preventing the associated complications of longer hospital stay. Although in our series, the number of patients is small and formal neuropsychological testing was not done, there were no neurocognitive complaints following treatment. We observed that patients aged over 60 years have better long-term control, with fewer cyst recurrences or tumor progression.

Moussa et al. treated 52 patients with cystic CPs using an Ommaya reservoir catheter to aspirate the cyst contents. In their series, 73% were stable over a follow-up period of 7 years and they hypothesize that collapse of the cyst enables communication of the terminal holes with the outside CSF spaces allowing egress of cyst fluid. The use of an Ommaya reservoir for drainage of cystic contents has been described in similar reports by Spaziante et al. and Al Ahbid et al. In our cases, the tumor cysts also appear to stabilize after catheter placement without the need for repeated aspirations. Although this could be related to a delayed effect of radiation on tumor fluid production, we believe it could be a combination of radiation, the above phenomenon and additionally the act of perforating the cyst wall, and insertion of the catheter, which by itself acts as a stent allowing cyst fluid to egress along its sides via capillary forces into the subarachnoid space [Figure 4a-e]. The catheter in our cases is placed at the deepest point within the cyst in our cases and even though the wall collapses around the catheter, it appears to be inadequate for a direct communication via the holes at the tip. Our algorithm for selecting and managing this subgroup of CP patients has been outlined [Figure 5]. The infrequent occurrence of these tumors, their varying presentation characteristics, and behavior makes it difficult to perform prospective randomized trials.

In literature, control rates appear to be better for solid or cystic tumors compared with mixed, large, and multi-cystic tumors, factors that predict poorer outcomes. Additionally cystic recurrences more frequently occur following GKRS, rather than progression of the solid tumor component, similar to what is seen in our patient cohort. In reports published prior to the 1980s, recurrence rates for CPs varied from 30% to 50%. Although numerous technological advances in image guided surgical systems and micro-techniques have been made since then, the results are only slightly better.

With variable results from surgery, data from the Royal Marsden hospital and Children’s hospital in Boston treating patients with conventional radiotherapy (CRT), reveal that a combination of surgery and radiotherapy or radiotherapy alone achieves excellent tumor control and survival. These early studies indicated the radiosensitive biology of these tumors. There was no significant difference seen in outcomes or survival in those patients who received upfront adjuvant RT and RT at the time of progression. Doses for CRT have ranged between 50 and 60 Gy with several authors reporting better control rates at doses >54 Gy. Karavitaki et al. and Stripp et al. found comparable 10-year survival in patients treated with CRT had risks of optic neuropathy ranging from...
9% to 30%,[20,24,66] neuropsychological sequel in 10-12.5% patients, and delayed hypothalamic-pituitary damage in up to 23%. Fractionated radiotherapy has been used since the 1990s[20,65] for the postoperative management of these tumors with good tumor control rates. The early series using CRT are described in Table 4.

Evolution in conformal RT techniques such as intensity modulated radiation therapy (IMRT), stereotactic fractionated radiotherapy, proton beam therapy, and SRS has been used more frequently for treating these tumors with good tumor control rates. The early series using CRT are described in Table 4.

Secondary malignancies.[54] Tumor control rates after SRS range from 33% to 90%.[11,30,34,61,64] Niranjan et al.[61] in their series of 46 patients report overall survival rates and control rates at 5 years of 97.1% and 68%, respectively. Complications with SRS include radiation-induced optic neuropathy that has been reported at doses of greater than 8-10 Gy[43,57,80] with factors like previous radiation in the region, volume of the optic apparatus exposed playing a role in the development of this complication.[25] Although SRS avoids the long-term complications associated with fractionated RT, mean morbidity rates are around 4%.[22] Kobayashi[13] and Chung[12] noted favorable quality of life outcomes in patients who responded to SRS. The various reported series using both GK are reported in Table 5.
Table 3: Review of results for microsurgical excision and radiotherapy for craniopharyngiomas

| Series                  | Year | No. | Complete % | Recurrence % | Partial % | Partial resection and RT % | Partial resection and RT % | Recurrence % |
|-------------------------|------|-----|------------|--------------|-----------|---------------------------|---------------------------|--------------|
| McKissock and Ford[37]  | 1966 | 45  | 0          | 0            | 0         | 0                         | 0                         | 0            |
| Kramer[30]              | 1968 | 16  | 0          | 0            | 0         | 0                         | 0                         | 0            |
| Tandon Sharma[71]       | 1974 | 18  | 0          | 0            | 0         | 0                         | 0                         | 0            |
| Katz[32]                | 1975 | 34  | 100        | 26           | 0         | 0                         | 0                         | 0            |
| McMurry[49]             | 1977 | 30  | 33         | 20           | 9         | 30                        | 11                        | 37           |
| Shapiro[30]             | 1979 | 38  | 58         | 23           | 9         | 24                        | 7                         | 18           |
| Laws[40]                | 1980 | 26  | 35         | 15           | 58        | 2                         | 8                         | 0            |
| Carmel[8]               | 1982 | 43  | 33         | 50           | 14        | 33                        | 14                        | 33           |
| Symon[74]               | 1985 | 20  | 100        | 5            | 0         | NA                        | NA                        | NA           |
| Sweet                   | 1988 | 43  | 93         | 10           | 3         | 7                         | NA                        | NA           |
| Yasargil[83]            | 1990 | 144 | 90         | 7            | 7         | NA                        | NA                        | NA           |
| Samii[84]               | 1991 | 34  | 97         | 9            | 1         | 3                         | NA                        | NA           |
| Konovalov[15]           | 1992 | 198 | 64         | NA           | 71        | 36                        | NA                        | NA           |
| Regine[84]              | 1993 | 56  | 21         | NA           | 5         | 9                         | 39                        | NA           |
| Duff[15]                | 2000 | 121 | 57         | 17           | NA        | 43                        | NA                        | NA           |
| Van Effentere and Boch[83] | 2002 | 122 | NA         | 59           | 13        | NA                        | 18                        | NA           |
| Minamida[52]            | 2005 | 37  | NA         | 70           | 15        | NA                        | 30                        | NA           |

NA: Not available, RT: Radiation therapy

Table 4: Summary results of main series using conventional radiation therapy for the treatment of craniopharyngiomas

| Authors              | No. treated | Year | Modality | Median dose (Gy) | Tumor size (ml) | Follow-up (months) | Control | Morbidity% |
|----------------------|-------------|------|----------|------------------|-----------------|--------------------|---------|------------|
| Regine[84]           | 58          | 1993 | CRT      | 56-62            | NA              | 17 years           | 82 at 10 years | NA         |
| Rajan[85]            | 173         | 1993 | CRT      | 50               | NA              | 12 years           | 83 at 10 and 79 at 20 years | 50         |
| Hetelekidis[36]a     | 37          | 1993 | CRT      | 54               | NA              | 49                 | 86 at 10 years | 60         |
| Habrand[23]a         | 37          | 1999 | CRT      | 50               | NA              | NA                 | 78 at 5 and 56.5 at 10 years | 40         |
| Merchant[50]a        | 15          | 2004 | CRT      | 54               | NA              | 72                 | 94 at 5 years | 80         |
| Varotto[44]          | 24          | 2002 | CRT      | 60               | NA              | 12 years           | 89 at 10 and 54 at 20 years | 20         |
| Stripp[74]           | 76          | 2004 | CRT      | 55               | NA              | 7.6 years          | 84 at 10 years | 20         |
| Pemberton[82]        | 87          | 2005 | CRT      | 43               | NA              | 8 years            | 77 at 10 and 66 at 20 years | 10         |
| Moon[94]             | 50          | 2005 | CRT      | 54               | 12              | 12.8 years         | 96 and 91 at 5 and 10 years | 15         |
| Merchant[51]a        | 28          | 2006 | CRT      | 55               | NA              | 36                 | 90 at 3 years | NA         |

CRT: Conventional radiotherapy, a: Pediatric series included, NA: Not applicable, Gy: Gray

Our patients receiving IMRT were treated with a standard dose of 54 Gy and the GKRS patients received marginal doses varying from 9 to 15 Gy with various series report marginal doses ranging from 3 to 25 Gy for long-term tumor control. Alternative dose plans prescribing lower margin doses with a high central dose at the same time avoid adverse radiation effects to adjacent organs at risk with good tumor control.[33] We prefer treating the tumor to the 50% isodose line and in cases where in the tumor and optic apparatus are in close proximity, the patients preferentially receive IMRT.

Alternative treatment options include intracavitary radiation and chemotherapy,[11] mainly used to treat recurrent cystic tumors. Pollock et al.[61] reported cyst control in 90.6% of patients using this treatment modality, however, Lunsford et al.[44] reported the ineffectiveness of intracavitary radiation for treating CPs with a more solid component. Installation of bleomycin into the cyst cavity has been advocated by Savas[69] and Takahashi[77] as an alternative, using its antineoplastic properties that interfere with DNA production, to suppress cyst fluid, and obliterate the cyst cavity.[11]

Although we tried to obtain histology in all our cases prior to treatment, this was not possible in four (4/11) patients. In two (2/4) of these patients, we attempted to biopsy the wall, however, doing a stereotactic biopsy of the cyst wall is technically challenging because of capsule shift after puncturing the wall, the associated adjacent vessels
and the deep seated location of the tumor mass. Of the remaining two (2/11) patients, one patient had undergone VP shunting elsewhere and another had undergone shunt insertion and GKRS following which they had presented to us for further management. Even though other lesions have to be considered in the differential diagnosis of sellar-suprasellar neuroimaging, with the age of the patient, clinical and laboratory findings along with computed tomography (CT) evidence of calcification and MRI imaging revealing heterogeneous enhancement of the solid component with a mixed solid-cystic sellar–suprasellar lesion, following a detailed discussion with the patient, both the patient and treating team decided to go ahead with our management strategy. Additional technical challenges associated with the stereotactic procedure are the appropriate placement of the Ommaya catheter accurately within the depth of the cyst. While histologically, papillary CPs are less likely to recur, we could not analyze our outcome based on histology because of the absence of adequate specimens in many of our cases. In our series we used a combination of RT techniques, including IMRT and GKRS and have observed good long-term outcomes.

The overall 10-year survival rates for CPs presently range from 85% to 90% and 62% to 76% at 20 years, with mortality beyond that infrequently due to disease progression. Mortini et al. recently reported a loss of independence in activities of daily living and a decreased quality of life on long-term follow up after surgery in CPs. Thus, in the treatment of carefully selected adult patients, alternative minimalistic treatment options have to be integrated into the management plan in order to avoid major morbidity related to surgery. Additional advantages include shorter hospital stays, maintaining their activity level, quality of life, and immediately resume their active lifestyle.

CONCLUSION

CP management requires an individualized, multi-disciplinary approach. Radical surgery is not justified in all cases, especially with adjunct treatment modalities now readily available. The good long-term control rates, low endocrine, visual and cognitive morbidity and minimal to no mortality, and short hospital stays make minimally invasive strategies a viable option for the long-term control of these tumors in the elderly and other well-selected patients.

REFERENCES

1. Al-Abyad AG, El-Sheikh EM. Management of grossly cystic craniopharyngioma by percutaneous aspiration and external beam irradiation. Egypt J Neurosurg 2006;21:123-37.
2. Albright AL, Hadjipanayis CG, Lunsford LD, Kondziolka D, Pollack IF, Adelson PD. Individualized treatment of pediatric craniopharyngiomas. Childs Nerv Syst 2005;21:649-54.
3. Amendola BE, Wolf A, Coy SR, Amendola MA. Role of radiosurgery in craniopharyngiomas: A preliminary report. Med Pediatr Oncol 2003;41:123-7.
4. Backlund EO. Treatment of craniopharyngiomas: The multimodality approach. Pediatr Neurosurg 1994;21 Suppl 1:82-9.
5. Barua KK, Kohmura E, Tamaki N. Treatment of recurrent craniopharyngiomas. Kobe J Med Sci 2003;49:123-32.
6. Baskin DS, Wilson CB. Surgical management of craniopharyngiomas: A preliminary report. Med Pediatr Oncol 2003;41:123-7.
7. Backlund EO. Treatment of craniopharyngiomas: The multimodality approach. Pediatr Neurosurg 1994;21 Suppl 1:82-9.
8. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89:547-51.
9. Carmel PW, Antunes JL, Chang CH. Craniopharyngiomas in children. Neurosurgery 1982;1:382-9.
Cavazzuti V, Fischer EG, Welch K, Bello JA, Winston KR. Neurological and psychophysiologica sequels following different treatments of craniopharyngioma in children. J Neurosurg 1983;59:409-17.

Chiu SM, Lunsford LD, Niranjan A, Kondziolka D, Flickinger JC. Stereotactic radiosurgery of residual or recurrent craniopharyngioma, after surgery, with or without radiation therapy. Neuro Oncol 2001;3:159-66.

Chung WY, Pan DH, Shiao CY, Guo WY, Wang LW. Gamma knife radiosurgery for craniopharyngioma. J Neurosurg 2000;93 Suppl 3:547-56.

Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007;109:2308-14.

Crowley RK, Hamnik OP, O’Sullivan EP, Behan LA, Smith D, Agha A, et al. Mortality and morbidity in patients with craniopharyngioma after surgery. Clin Endocrinol 2010;73:5-16.

Duff J, Meyer FB, Istrup DM, Laws ER, Jr, Schlech CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngioma. Neurosurgery 2000;46:291-302.

Erfurth EM, Holmer H, Hjalildal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary 2013;16:46-55.

Fahlbusch R, Hofmann BM. Surgical management of craniopharyngiomas. Acta Neurochir (Wien) 2008;150:1213-26.

Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: Experience with 168 patients. J Neurosurg 1999;90:337-50.

Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: Long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006;64:1348-54.

Flickinger JC, Lunsford LD, Singer J, Cano ER, Deutsch M. Megavoltage external beam irradiation of craniopharyngiomas: Analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 1990;19:117-22.

Gardner PA, Kassam AB, Snyderman CH, Carrau RL, Mintz AH, Grahovac S, et al. Outcomes following endoscopic, expanded endonasal resection of suprasellar craniopharyngioma: A case series. J Neurosurg 2008;109:6-16.

Gopalan R, Dassoulas K, Rainey J, Sherman JH, Sheehan JP. Evaluation of the role of Gamma Knife surgery in the treatment of craniopharyngiomas. Neurosurg Focus 2008;24:E5.

Habrand JL, Saran F, Alapetite C, Noel G, El Boustany R, Grill J. Radiation therapy in the management of craniopharyngiomas: Current concepts and future developments. J Pediatr Endocrinol Metab 2006;19 Suppl 1:389-94.

Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 1976;170:167-71.

Hasgawa T, Kobyashi T, Kida Y. Tolerance of the optic apparatus in radiosurgery of residual or recurrent craniopharyngioma, after surgery, with or without radiation therapy. Neuro Oncol 2001;3:159-66.

Kramer S. The value of radiation therapy for pituitary and parapituitary tumours. Can Med Assoc J 1969;89:1120-7.

Kramer S, McKissock W, Concannon JP. Craniopharyngiomas. Treatment by combined surgery and radiation therapy. J Neurosurg 1961;18:217-26.

Lapras C, Patel JD, Mottolese C, Gharbi S, Lapras C Jr. Craniopharyngiomas in childhood: Analysis of 42 cases. Prog Exp Tumor Res 1987;30:350-8.

Laws ER. Craniopharyngiomas in children and young adults. Prog Exp Tumor Res 1987;30:335-40.

Laws ER. Jr, Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980;52:661-4.

Laws ER, Jr, Traumtum JC, Hollenhorst RW Jr. Transsphenoidal decompression of the optic nerve and chiasm. Visual results in 62 patients. J Neurosurg 1977;46:717-22.

Leber KA, Bergloff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 1998;88:43-50.

Lunsford LD, Gumerman L, Levine G. Stereotactic intracavitary irradiation of cystic neoplasms of the brain. Appl Neurophysiol 1985;48:146-50.

Lunsford LD, Kondziolka D, Flickinger JC. Stereotactic radiosurgery for benign intracranial tumors. Clin Neurosurg 1993;40:475-97.

Maia G, Aniece C, Rossi GE, Colosimo C. Surgical treatment of craniopharyngiomas: An evaluation of the transsphenoidal and pterional approaches. Neurosurgery 1995;36:715-24.

Mark RJ, Lutge WR, Shimizu KT, Tinan LM, Selch MT, Parker RG. Craniopharyngioma: Treatment in the CT and MR imaging era. Radiology 1995;197:195-8.

Matsen DD, Crigrler JF Jr. Management of craniopharyngioma in childhood. J Neurosurg 1969;30:377-90.

McMurry FG, Hardy RW Jr, Dohn DF, Sadar E, Gardner WJ. Long-term results in the management of craniopharyngiomas. Neurosurgery 1977;1:238-41.

Merchant TE. Craniopharyngioma radiotherapy: Endocrine and cognitive effects. J Pediatr Endocrinol Metab 2006;19 Suppl 1:S43-49.

Merchant TE. Kiehna EN, Kun LE, Mulhern RK, Li C, Xiong X, et al. Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function. J Neurosurg 2006;104 Suppl 2:594-102.

Minamida Y, Mikami T, Hashi K, Houlkin K. Surgical management of the recurrence and regrowth of craniopharyngiomas. J Neurosurg 2005;103:224-32.

Minniti G, Esposito V, Amichetti M, Enrici RM. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev 2009;32:125-32.

Minniti G, Saran F, Tratch D, Soomal R, Ardell S, Gonsales A, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 2007;82:90-5.

Mokry M. Craniopharyngiomas: A six year experience with Gamma Knife radiosurgery. Stereotact Funct Neurosurg 1999;72 Suppl 1:S140-9.

Moon SH, Kim IH, Park SW, Kim I, Hong S, Park CI, et al. Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas—a study in single institute. Childs Nerv Syst 2005;21(8-9):799-807.

Morita A, Coffery RJ, Foote RL, Schiff D, Gorman D. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: Experience in 88 patients. J Neurosurg 1999;90:42-9.

Mortini P, Losa M, Pozzobon G, Barzaghi R, Riva M, Acerno S, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. J Neurosurg 2009;78:64-71.

Nimsky C, Ganslandt O, Hofmann B, Fahlbusch R. Limited benefit of Gamma Knife radiosurgery. Stereotact Funct Neurosurg 1999;72 Suppl 1:S14-6.

Niranjan A, Kano H, Mathieu D, Kondziolka D, Flickinger JC, Lunsford LD. Radiosurgery for Craniopharyngioma. Int J Radiat Oncol Biol Phys 2010;78:64-71.
62. Pemberton LS, Dougall M, Magee B, Gatzamaneni HR. Experience of external beam radiotherapy given adjuvantly or at relapse following surgery for craniopharyngioma. Radiother Oncol 2005;77:99-104.

63. Pollock BE, Lunsford LD, Kondziolka D, Levine G, Flickinger JC. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: Current technique and long-term results. Int J Radiat Oncol Biol Phys 1995;33:437-46.

64. Prasad D, Steiner M, Steiner L. Gamma knife surgery for craniopharyngioma. Acta Neurochir (Wien) 1995;134:167-76.

65. Rajan B, Ashley S, Gorman C, Jose CC, Horwich A, Bloom Hj, et al. Craniopharyngioma--A long-term results following limited surgery and radiotherapy. Radiother Oncol 1993;26:1-10.

66. Regine WF, Mohiuddin M, Kramer S. Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation. Radiother Oncol 1993;27:13-21.

67. Rutka JT. Craniopharyngioma. J Neurosurg 2002;97:1-2.

68. Samii M, Bini W. Surgical treatment of craniopharyngiomas. Zentralbl Neurochir 1991;52:17-23.

69. Savas A, Arasil E, Batay F, Selcuki M, Kanpolat Y. Intracavitary chemotherapy of polycystic craniopharyngioma with bleomycin. Acta Neurochir (Wien) 1999;141:547-8; discussion 549.

70. Shapiro K, Till K, Grant DN. Craniopharyngioma in childhood. A rational approach to treatment. J Neurosurg 1979;50:617-23.

71. Sharma U, Tandon PN, Saxena KK, Singhal RM, Baruah JD. Craniopharyngiomas treated by a combination of surgery and radiotherapy. Clin Radiol 1974;25:13-7.

72. Shi XE, Wu B, Fan T, Zhou ZQ, Zhang YL. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008;110:151-9.

73. Spaziante R, De Divitis E, Irace C, Cappabianca P, Caputi F. Management of primary or recurring grossly cystic craniopharyngiomas by means of draining systems. Topic review and 6 case reports. Acta Neurochir (Wien) 1989;97:95-106.

74. Stripp DC, Maity A, Janss Aj, Belasco JB, Tochner ZA, Goldwein JW, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004;58:714-20.

75. Sweet WH. Radical surgical treatment of craniopharyngioma. Clin Neurosurg 1976;23:52-79.

76. Symon L, Sprich W. Radical excision of craniopharyngioma. Results in 20 patients. J Neurosurg 1985;62:174-81.

77. Takahashi H, Nakazawa S, Shimura T. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 1985;62:120-7.

78. Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM. Endocrine and neurologic outcome in childhood craniopharyngioma: Review of effect of treatment in 42 patients. J Pediatr 1980;97:728-35.

79. Till K. Craniopharyngioma. Childs Brain 1982;9:179-87.

80. Tishler RB, Loeffler JS, Lunsford LD, Duma C, Alexander E 3rd, Kooy HM, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993;27:215-21.

81. Tomita T, McLone DG. Radical resections of childhood craniopharyngiomas. Pediatr Neurosurg 1993;19:6-14.

82. Ulfarsson E, Lindquist C, Roberts M, Rahn T, Lindquist M, Thoren M, et al. Gamma knife radiosurgery for craniopharyngiomas: Long-term results in the first Swedish patients. J Neurosurg 2002;97 Suppl 5:613-22.

83. Van Effenterre R, Boch AL. Craniopharyngioma in adults and children: A study of 122 surgical cases. J Neurosurg 2002;97:3-11.

84. Variot 0, K, Flickinger JC, Kondziolka D, Lunsford LD, Deutsch M. External beam irradiation of craniopharyngiomas: Long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002;54:492-9.

85. Visser J, Huijg J, Sargent M, Steinbok P, Goddard K, Fryer C. Late mortality in pediatric patients with craniopharyngioma. J Neurooncol 2010;100:105-11.

86. Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, et al. Craniopharyngiomas: A clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 1994;35:1001-10; discussion 1010-1.

87. Yasargil MG, Curcic M, Kis M, Siegenthaler G, Teddy P, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg 1990;73:3-11.

88. Zoicas F, Schoff C. Craniopharyngioma in adults. Front Endocrinol (Lausanne)